Constella Group and SAS are rolling out what they describe as a “turnkey” solution for clinical drug and medical device trials.

The product is called Constella Orion Powered by SAS Drug Development.

It will be made available through an application service provider format, integrating applications that merge day-to-day planning and execution of trials along with data integration and analysis. It is available for license for companies involved in Phase II and up clinical trials.

The companies introduced the product at the Drug Information Association conference in Washington, DC.

“Together with SAS, we are creating a seamless, end-to-end drug development platform unlike any other on the market,” said Donald Holzworth, CEO of Constella, in a statement. “This highly affordable platform is designed to increase R&D efficiency, improve collaboration and information exchange among study teams and sponsors, and accelerate time to market with excellent regulatory support and direction.”

According to SAS, the integrated solution offers a variety of advantages.

“With the integration of SAS Drug Development and Constella Orion, customers will not only manage, but truly collaborate around life sciences research programs through a secure, Web-based environment that provides the regulatory support that is required,” said Kecia Serwin, general manager of SAS Health and Life Sciences group, in a statement. “All authorized users will have real-time access to research data, allowing them to drill down, extract and analyze study data, without the aid of a programmer and without having to change their work environments. This way, customers can readily obtain critical intelligence to make fast and well-informed go/no-go decisions throughout the development process.”

Constella Group: